The group’s median market cap performance was positive

Plus: Roche’s Alecensa meets in ALK-positive NSCLC and updates from Carisma and FindCure

11 biopharmas raised $968M in April. A fast start to May could rekindle momentum

Plus: Foghorn pauses targeted degrader study and updates from bluebird, Lilly, MaaT, Biosion

Plus: Clinical hold lifted on Astellas gene therapy, FDA reviewers scrutinize rezafungin’s benefit and updates from Deciphera, Disc and more

With big market cap gain, investors could see broader promise of biotech’s approach

In $4.1B deal, pharma pays more than double the biotech’s market valuation to gain targeted lung cancer therapy repotrectinib

Plus Kaundinya named president and CEO at GlycoERA, and updates from Plexium, Alentis, ADCendo, Xcell and more

Plus: What, me worry? Arcellx goes public amid downdraft; and updates from Regio, J&J, Sanofi, PrecisionLife